|
| 37503880 | High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience. | Neuro Oncol | 2024 |
| 37503880 | High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience. | Neuro Oncol | 2024 |
| 36548930 | Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. | J Clin Oncol | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 35789275 | Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome. | Neuro Oncol | 2023 |
| 37643637 | Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma. | J Natl Compr Canc Netw | 2023 |
| 37343136 | Cerebellar mutism is linked to midbrain volatility and desynchronization from speech cortices. | Brain | 2023 |
| 37013660 | A sellar presentation of a WNT-activated embryonal tumor: further evidence of an ectopic medulloblastoma. | Acta Neuropathol Commun | 2023 |
| 36548930 | Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. | J Clin Oncol | 2023 |
| 37522896 | DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts. | Acta Neuropathol | 2023 |
| 37522896 | DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts. | Acta Neuropathol | 2023 |
| 37643637 | Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma. | J Natl Compr Canc Netw | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 35789275 | Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome. | Neuro Oncol | 2023 |
| 37013660 | A sellar presentation of a WNT-activated embryonal tumor: further evidence of an ectopic medulloblastoma. | Acta Neuropathol Commun | 2023 |
| 37343136 | Cerebellar mutism is linked to midbrain volatility and desynchronization from speech cortices. | Brain | 2023 |
| 34351088 | Rare cases of medulloblastoma with hypermutation. | Cancer Rep (Hoboken) | 2022 |
| 35463474 | Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. | STAR Protoc | 2022 |
| 35395680 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). | Neuro Oncol | 2022 |
| 35709750 | Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma. | Mol Cancer Ther | 2022 |
| 35380295 | The posterior fossa syndrome questionnaire: using science to inform practice. | J Neurooncol | 2022 |
| 36131015 | Unified rhombic lip origins of group 3 and group 4 medulloblastoma. | Nature | 2022 |
| 35798383 | Primary cilia control translation and the cell cycle in medulloblastoma. | Genes Dev | 2022 |
| 35982322 | Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. | Acta Neuropathol | 2022 |
| 35720861 | Reducing Wait Time in a High-volume Pediatric Neuro-oncology Clinic by Optimizing Process Flow: A Quality Improvement Project. | Pediatr Qual Saf | 2022 |
| 34351088 | Rare cases of medulloblastoma with hypermutation. | Cancer Rep (Hoboken) | 2022 |
| 34446453 | <sup>11</sup>C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. | J Nucl Med | 2022 |
| 34894262 | Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. | Neuro Oncol | 2022 |
| 34934181 | Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. | Lab Invest | 2022 |
| 35709750 | Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma. | Mol Cancer Ther | 2022 |
| 35380295 | The posterior fossa syndrome questionnaire: using science to inform practice. | J Neurooncol | 2022 |
| 35798383 | Primary cilia control translation and the cell cycle in medulloblastoma. | Genes Dev | 2022 |
| 35463474 | Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. | STAR Protoc | 2022 |
| 35395680 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). | Neuro Oncol | 2022 |
| 35720861 | Reducing Wait Time in a High-volume Pediatric Neuro-oncology Clinic by Optimizing Process Flow: A Quality Improvement Project. | Pediatr Qual Saf | 2022 |
| 36131015 | Unified rhombic lip origins of group 3 and group 4 medulloblastoma. | Nature | 2022 |
| 35982322 | Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. | Acta Neuropathol | 2022 |
| 34934181 | Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. | Lab Invest | 2022 |
| 34894262 | Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. | Neuro Oncol | 2022 |
| 34446453 | <sup>11</sup>C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. | J Nucl Med | 2022 |
| 33472956 | Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. | Sci Transl Med | 2021 |
| 33472956 | Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. | Sci Transl Med | 2021 |
| 33737307 | Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. | Clin Cancer Res | 2021 |
| 34215733 | Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. | Nat Commun | 2021 |
| 33823018 | Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. | Neuro Oncol | 2021 |
| 33502920 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. | J Clin Oncol | 2021 |
| 34301788 | Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. | Cancer Discov | 2021 |
| 33025730 | Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. | Pediatr Blood Cancer | 2021 |
| 33405951 | Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). | J Clin Oncol | 2021 |
| 33405376 | A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). | Pediatr Blood Cancer | 2021 |